News

August 1, 2019

EIP Pharma to Present at Canaccord Genuity 39th Annual Growth Conference

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that company management will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019, at 12:00 p.m. ET in Boston, MA.

Read More

July 17, 2019

EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process

Presentations at Late Breaker Session at Alzheimer’s Association International Conference (AAIC) 2019 Cambridge, Mass., July 17, 2019 – EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that new preclinical data regarding neflamapimod were presented at the AAIC 2019 scientific meeting in Los Angeles, CA (July 14-18, 2019). “The findings add to the growing body […]

Read More

July 12, 2019

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies

The primary objective of the study is to determine whether neflamapimod, a brain-penetrant, oral small molecule that inhibits the enzyme p38 alpha, can reverse the hippocampal synaptic dysfunction associated with DLB. 

Read More

July 9, 2019

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington’s Disease

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington’s disease

Read More

July 8, 2019

EIP Pharma Appoints Noel Donnelly as CFO

EIP Pharma, Inc. a CNS-focused therapeutics company, today announced that it has expanded its leadership team with the appointment of Noel Donnelly as CFO. Mr. Donnelly joins EIP Pharma from Takeda Pharmaceuticals where he led a group focused on strategy and operations.

Read More

June 7, 2019

EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer’s Disease and Dementia with Lewy Bodies

CAMBRIDGE, Mass., June 7, 2019 /PRNewswire/ — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that the Company will host a key opinion leader (KOL) breakfast briefing focused on the potential of neflamapimod in Alzheimer’s disease and Dementia with Lewy bodies on Friday, June 21st, 2019 at 8:00 a.m. ET in New York City. The event will feature guest speakers Steven […]

Read More

May 31, 2019

EIP Pharma to Present at Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 31, 2019 /PRNewswire/ — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that company management will present at two investor conferences in June. Jefferies 2019 Healthcare Conference Date: Friday, June 7th, 2019 Time: 9:00 a.m. ETLocation: New York, NY JMP Securities Life Sciences Conference Date: Thursday, June 20th, 2019 Time: 1:00 p.m. ETLocation: New York, NY A live audio webcast of both presentations […]

Read More

April 15, 2019

EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications

CAMBRIDGE, Mass., April 15, 2019 /PRNewswire/ — EIP Pharma, a CNS-focused therapeutics company, announced today the successful completion of $11.2 million in new private funding to explore the use of the investigational drug neflamapimod as a treatment for dementia with Lewy bodies and for the cognitive deficits in Huntington’sdisease. Phase 2 clinical studies in these new disease indications for neflamapimod are […]

Read More

February 11, 2019

EIP Pharma to Present at BIO CEO Investor Conference

CAMBRIDGE, Mass., February 11, 2019 — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that company management will present at the BIO CEO Investor Conference. The presentation will take place at 10:00 a.m. ET on February 12, 2019 in New York City. A live audio webcast of the event will be available on the […]

Read More

December 13, 2018

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

CAMBRIDGE, Mass., Dec 13, 2018 /PRNewswire/ — EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, announced today that it has fully enrolled the REVERSE-SD study, a placebo controlled, Phase 2b trial of the investigational drug neflamapimod in patients with Early Alzheimer’s disease. The Phase 2b trial is being conducted in the United States, United Kingdom, Netherlands, Denmark and the Czech Republic. Neflamapimod is a brain-penetrant oral small […]

Read More

October 24, 2018

EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer’s Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment

Phase 2b study (REVERSE-SD) of neflamapimod in Early Alzheimer’s disease more than 50 percent enrolled

Read More

May 16, 2018

EIP Pharma Secures $20.5 Million in Series B Financing

Proceeds to Support Continued Development of Neflamapimod for Alzheimer’s Disease

Read More

March 7, 2018

EIP Pharma Announces Publication of Positive Alzheimer’s Disease Clinical Study Data with Neflamapimod

Phase 2a Results Published in Annals of Clinical and Translational Neurology Demonstrate Statistically Significant Improvement in Episodic Memory Function in Patients with Alzheimer’s Disease

Company Initiates Phase 2b (REVERSE-SD) Confirmatory Study with Neflamapimod

Read More


July 18, 2017

EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer’s Association International Conference (AAIC)

Evidence that neflamapimod improves episodic memory function in patients with Early Alzheimer’s disease

Read More

November 8, 2016

EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer’s Disease

CAMBRIDGE, Mass., Dec. 8, 2016 /PRNewswire/ — EIP Pharma, LLC (www.eippharma.com) today announced that it has obtained proof-of-mechanism for neflamapimod (previously code named VX-745), with the results of two recently completed Phase 2a clinical trials that demonstrated significant Alzheimer’s disease relevant pharmacological activity.  The findings from Study 302 (12-week treatment) and Study 303 (6-week treatment) are the subject […]

Read More

September 28, 2016

EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer’s disease and ischemic stroke recovery

Patents provide broad coverage for administering VX-745 to treat Alzheimer’s disease and/or promote recovery after acute ischemic stroke

Read More

December 16, 2015

EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor

CAMBRIDGE, Mass., Dec. 16, 2015 /PRNewswire/ — EIP Pharma LLC today announced the publication in the Journal of Alzheimer’s Disease of an article entitled “Selective brain-targeted antagonism of p38 MAPK alpha reduces hippocampal IL-1 beta levels and improves Morris-Water-Maze Performance in Aged Rats,” which demonstrates pro-cognitive effects of VX-745 for the first time. “These results demonstrate the potential of p38 MAPK […]

Read More

June 3, 2015

EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer’s disease (AD)

First-ever human clinical studies designed to assess the effects of selective p38 alpha kinase inhibition on brain amyloid plaque load and inflammation in patients with Mild Cognitive Impairment (MCI) due to AD or mild AD

Read More

About EIP

Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.

Contact Us